Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Anthera Pharmaceuticals' 6.0M common stock public offering: Merriman Curhan Ford acts as co-manager

Merriman Curhan Ford Group, Inc. was a co-manager in Anthera Pharmaceuticals, Inc.'s public offering of 6.0 million shares of common stock.

6 Mar 2010

Anthera Pharmaceuticals completes initial public offering at $7.00 per share

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the completion of its initial public offering of six million shares of common stock at a price of $7.00 per share. The net proceeds of the offering to Anthera, after deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, were approximately $36.7 million.

5 Mar 2010

RMR can non-invasively, quickly and accurately detect presence of sCAD

Newly published data shows using a Respiratory Modulation Response (RMR) is a novel, non-invasive measure to quickly and accurately detect the presence of significant coronary artery disease (sCAD). Patients in the study with sCAD had a lower RMR compared to patients without, regardless of their risk factors or clinical history of angina, previous myocardial infarction (MI), or angioplasty.

3 Mar 2010

Evolving sex disparity in midlife stroke prevalence: Further study needed

When it comes to stroke prevalence, it appears that the gender gap is widening. According to a new report from a researcher at the Keck School of Medicine of the University of Southern California (USC), women between the ages of 35 and 64 are almost three times more likely to have a stroke compared to men in the same age group.

26 Feb 2010

Resverlogix commences enrollment in RVX-208 Phase 2 clinical trial for atherosclerosis in ACS patients

Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.

26 Feb 2010

BioMedix Vascular Solutions, Howard University Hospital to participate in Community Health Project and Demonstration

BioMedix Vascular Solutions, Inc. announced today that the company has partnered with Howard University Hospital, Department of Surgery to participate in a Community Health Project and Demonstration focused on diagnosing and treating the potentially life-threatening condition called Peripheral Arterial Disease (PAD).

25 Feb 2010

Stereotaxis' revenue for recent fourth-quarter increases 16%

Stereotaxis, Inc. today reported its financial results for the quarter and the year ended December 31, 2009. Revenue for the recent fourth quarter grew 16% to $14.1 million compared with $12.1 million in the same quarter a year ago.

25 Feb 2010

BioMedix Vascular Solutions, Howard University Hospital partner to help uninsured PAD patients

24 Feb 2010

New treatments for heart disease

Two studies published in the latest issue of Cell Transplantation (18:12) may lead to new treatments for the treatment of heart diseases. The first study, carried out by a team of Brazilian researchers, found that cell transplantation of bone marrow mononuclear cells (BMMCs) directly into the heart benefited patients suffering from refractory angina.

24 Feb 2010

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

Forest Laboratories, Inc. announced today that the U.S. Food and Drug Administration did not approve the additional indication for Bystolic® (nebivolol) tablets as a treatment for stable chronic heart failure (CHF) as requested in the company’s Supplemental New Drug Application (sNDA).

23 Feb 2010

DNA interval in unexplored region of human genome increases risk for coronary artery disease

Scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory have learned how an interval of DNA in an unexplored region of the human genome increases the risk for coronary artery disease, the leading cause of death worldwide.

23 Feb 2010

New cardiac imaging technique reduces radiation exposure compared to standard helical scan

In a new study published in the March issue of Radiology, researchers from Columbia University and the National Heart, Lung and Blood Institute have determined that an imaging exam of the heart using the latest generation of CT technology exposes patients to as much as 91 percent less radiation than standard helical CT scanning.

23 Feb 2010

Two genetic alterations linked to benign enzyme condition keep hepatitis C patients anemia-free

Many people who undergo treatment for hepatitis C develop hemolytic anemia, a disorder that destroys red blood cells. In some cases, it is so severe they have to reduce their medication or stop therapy altogether. But now, scientists in Duke University's Institute for Genome Sciences & Policy have discovered two genetic alterations linked to a benign enzyme condition that keep some patients anemia-free.

21 Feb 2010

Study reveals underrepresentation of women in cardiovascular clinical trials

Women are substantially underrepresented in clinical trials used to formulate women's guidelines and are affected more than men by low social support after a heart attack, according to two studies in the women-themed issue of Circulation: Cardiovascular Quality and Outcomes, a journal of the American Heart Association.

20 Feb 2010

Cappella promotes serial IVUS analysis & Sideguard 3.25 device at Rome JIM

Cappella, Inc. (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, promoted their serial IVUS analysis & Sideguard® 3.25 device during the Joint Interventional Meeting (JIM) in Rome. Gary S. Mintz, MD, Cardiovascular Research Foundation, New York, USA presented "Positive Vessel Remodeling Using Sideguard in Coronary Bifurcations" during the New Technologies 1 Symposium.

20 Feb 2010

Researchers identify specific metabolic profiles that predict risk of heart attack and death

Tiny bits of molecular "trash" found in circulating blood appear to be good predictors of cardiovascular disease and untimely death, say researchers at Duke University Medical Center.

19 Feb 2010

Tryton Medical announces implantation of Tryton stent for the first time in Portugal and Austria

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the Tryton® stent has been implanted for the first time in Portugal and Austria.

19 Feb 2010

Cardiac ablation procedure performed with Stereotaxis System featured on recent BBC documentary

Stereotaxis announced that the recent BBC documentary "From the Heart" included a cardiac ablation procedure performed with the Stereotaxis System by Dr. Muchtiar Khan of OLVG Hospital in Amsterdam. The program's second half, beginning at 10:30 of the 25-minute run time, features extensive scenes from the Stereotaxis procedure.

18 Feb 2010

Generx clinical development opportunities: bioRASI to assist Cardium

Cardium Therapeutics today announced that it has entered into an agreement with bioRASI, an international contract research organization, to assist Cardium in the evaluation of Generx clinical development opportunities within major newly-industrializing markets in Eastern Europe, Asia and Latin America, for patients with chronic coronary artery disease who are either not optimal candidates for or do not have access to costly angioplasty/stenting or cardiac bypass surgery procedures.

17 Feb 2010

Routine testing of hs-CRP in women with heart disease is controversial, says Mayo Clinic cardiologist

For women concerned about heart disease, routine testing of high-sensitivity C-reactive protein (hs-CRP) is controversial, says Thomas Behrenbeck, M.D., Ph.D., a Mayo Clinic cardiologist, in an interview in the February issue of Mayo Clinic Women's HealthSource.

12 Feb 2010

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Anthera Pharmaceuticals' 6.0M common stock public offering: Merriman Curhan Ford acts as co-manager

Anthera Pharmaceuticals completes initial public offering at $7.00 per share

RMR can non-invasively, quickly and accurately detect presence of sCAD

Evolving sex disparity in midlife stroke prevalence: Further study needed

Resverlogix commences enrollment in RVX-208 Phase 2 clinical trial for atherosclerosis in ACS patients

BioMedix Vascular Solutions, Howard University Hospital to participate in Community Health Project and Demonstration

Stereotaxis' revenue for recent fourth-quarter increases 16%

BioMedix Vascular Solutions, Howard University Hospital partner to help uninsured PAD patients

New treatments for heart disease

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

DNA interval in unexplored region of human genome increases risk for coronary artery disease

New cardiac imaging technique reduces radiation exposure compared to standard helical scan

Two genetic alterations linked to benign enzyme condition keep hepatitis C patients anemia-free

Study reveals underrepresentation of women in cardiovascular clinical trials

Cappella promotes serial IVUS analysis & Sideguard 3.25 device at Rome JIM

Researchers identify specific metabolic profiles that predict risk of heart attack and death

Tryton Medical announces implantation of Tryton stent for the first time in Portugal and Austria

Cardiac ablation procedure performed with Stereotaxis System featured on recent BBC documentary

Generx clinical development opportunities: bioRASI to assist Cardium

Routine testing of hs-CRP in women with heart disease is controversial, says Mayo Clinic cardiologist

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in